Show simple item record

dc.date.accessioned2021-12-15T15:15:30Z
dc.date.available2021-12-15T15:15:30Z
dc.date.issued2021-12-15
dc.identifier.citationHEARTS in the Americas Regulatory Pathway to the Exclusive Use of Validated Blood Pressure Measuring Devices. Washington, D.C.: Pan American Health Organization; 2021. License: CC BY-NC-SA 3.0 IGO. https://doi.org/10.37774/9789275124864.en_US
dc.identifier.isbn978-92-75-12485-7 (Print)
dc.identifier.isbn978-92-75-12486-4 (PDF)
dc.identifier.urihttps://iris.paho.org/handle/10665.2/55382
dc.description.abstractCardiovascular disease (CVD) is the leading cause of disease burden globally. According to the 2017 Global Burden of Disease estimates, there were 14 million new cases of CVD, 80 million people living with this condition, and nearly 1 million deaths attributed to CVD in the Americas. Hypertension is the major risk factor for CVD, causing half of the cases, and is highly prevalent, affecting one in four adults, including 40% of those over age 25 years.To appropriately detect hypertension, accurate measurement of blood pressure is critical, and inaccurate measurement of BP has important consequences for policies to address hypertension, as well as for patient safety and quality of care. The Fourth World Health Organization (WHO) Global Forum on Medical Devices identified several critical issues related to medical devices. Among those issues were recommendations for increased regulation of medical devices in low- and middle-income countries and development of technical specifications to optimize procurement of priority medical devices. World Health Assembly Resolution 67.20 (Regulatory system strengthening for medical products) stresses the importance of regulation of medical devices for better public health outcomes and to increase access to safe, effective, and quality medical products. This publication seeks to contribute to meeting these recommendations by providing a practical tool for governments to improve their national regulatory frameworks to improve accuracy of blood pressure measuring devices (BPMDs), in turn contributing to the exclusive use of accuracy validated automated BPMDs in primary health care (PHC) facilities by 2025. This publication can also guide the development of procurement mechanisms that will ensure exclusive availability of BPMDs in PHC facilities. Specifically, this publication will provide a brief background on the importance of using validated BPMDs and highlight key elements of regulations related to pre-market approvals to promote accurate BPMDs.en_US
dc.language.isoenen_US
dc.publisherPAHOen_US
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 IGO*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/igo/*
dc.subjectNoncommunicable Diseasesen_US
dc.subjectCardiovascular Diseasesen_US
dc.subjectBlood Pressureen_US
dc.subjectBlood Pressure Monitorsen_US
dc.subjectHypertensionen_US
dc.subjectHeart Diseasesen_US
dc.subjectMortalityen_US
dc.subjectHearten_US
dc.titleHEARTS in the Americas: Regulatory Pathway to the Exclusive Use of Validated Blood Pressure Measuring Devicesen_US
dc.typeProcedures, manuals, guidelinesen_US
dc.rights.holderPan American Health Organizationen_US
dc.contributor.corporatenamePan American Health Organizationen_US
paho.isfeatured0en_US
paho.publisher.countryUnited Statesen_US
paho.publisher.cityWashington, D.C.en_US
dc.identifier.doihttps://doi.org/10.37774/9789275124864
paho.source.centercodeUS1.1en_US
paho.contributor.departmentNoncommunicable Diseases and Mental Health (NMH)en_US
paho.iswhotranslationNoen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 3.0 IGO
This notice should be preserved along with the article's original URL.Attribution-NonCommercial-ShareAlike 3.0 IGO